
Abbott Laboratories statistics
$108.52+1.18%Close 13 Nov 2026 · Market value $188.1B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Abbott Laboratories is valued at $188.1B on its latest close. Its price is 40.0 times its earnings.
| Market value | $188.1B |
|---|
| Enterprise value | $215.4B |
|---|
| Price / earnings | 40.03 |
|---|
| Price / sales | 3.90 |
|---|
| Price / book | 3.69 |
|---|
| EV / EBITDA | 20.40 |
|---|
| EV / sales | 4.47 |
|---|
| Price / free cash flow | 27.84 |
|---|
| Price / free cash flow, own 5-year average | 29.11 |
|---|
| EV / EBIT | 32.34 |
|---|
| EV / free cash flow | 31.82 |
|---|
| Free cash flow yield | 3.6% |
|---|
| Dividend yield | 2.3% |
|---|
Share price
| Latest close | $108.52 |
|---|
| Day's change | +1.2% |
|---|
| 52-week high | $132.03 |
|---|
| 52-week low | $81.97 |
|---|
| From 52-week high | −17.8% |
|---|
| Return · 1 month | +3.5% |
|---|
| Return · 3 months | −4.9% |
|---|
| Return · year to date | −13.4% |
|---|
| Return · 1 year | −15.8% |
|---|
| Beta · 1 year against the S&P 500 | 0.07 |
|---|
| 50-day average | $103.91 |
|---|
| 200-day average | $101.56 |
|---|
| RSI 14 | 54.1 |
|---|
| Average volume · 20 sessions | 9.5M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 56.4% |
|---|
| Operating margin | 18.2% |
|---|
| Net margin | 14.7% |
|---|
| Free cash flow margin | 16.7% |
|---|
| Return on equity | 13.1% |
|---|
| Return on assets | 7.4% |
|---|
| Return on invested capital | 9.9% |
|---|
| Return on invested capital, 5-year average | 11.4% |
|---|
| Return on capital employed | 11.7% |
|---|
| Stock-based compensation / revenue | 1.5% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $8.52B |
|---|
| Total debt | $14.14B |
|---|
| Net debt | $5.20B |
|---|
| Current ratio | 1.58 |
|---|
| Quick ratio | 0.83 |
|---|
| Debt / equity | 0.27 |
|---|
| Net debt / EBITDA | 0.47 |
|---|
| Interest coverage | 16.33 |
|---|
Growth
| Revenue, latest quarter on a year | +14.5% |
|---|
| Revenue, twelve months on a year | +10.0% |
|---|
| EPS, latest quarter on a year | −43.6% |
|---|
| EPS, twelve months on a year | −66.1% |
|---|
| Revenue, 5-year compound | +5.1% |
|---|
| Revenue, 10-year compound | +8.1% |
|---|
| Net income, 5-year compound | +7.7% |
|---|
| Free cash flow, 5-year compound | +5.3% |
|---|
| EPS, 5-year compound | +8.2% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 1.7B |
|---|
| Shares outstanding, 5-year compound | −0.4% |
|---|
| Net share repurchases | $497.0M |
|---|
| Dividends per share | $2.40 |
|---|
| Dividend payout | 63.1% |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $1.94B |
|---|
| Effective tax rate | 22.9% |
|---|
ABT in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.